

# InnoSer

Expertise & services
for your drug development journey

InnoSer | a smart road to better health

# Customized Preclinical Services

No matter at which stage of the drug development pipeline you are, InnoSer's experts take your preclinical research to the next level. InnoSer provides you with specialized in vitro and in vivo drug screening services, including pharmacokinetics/pharmacodynamics, biodistribution studies, toxicology testing, efficacy testing, bioanalytical and histopathology services.

Whether you work with small molecules, biologics, ATMPs, vaccines or medical devices, InnoSer's broad portfolio is designed to accelerate your novel therapeutics development with robust complimentary models and readouts spanning from oncology, cardiometabolic diseases, neurological disorders to rare genetic diseases.

## InnoSer is Your Trusted Preclinical Research Partner: 4 Pillars to Support Your Smart Road to Better Health

### Proactivity

We proactively seek and apply innovative solutions in everything we do to ensure that we provide you with scientific excellence.

### Collaboration

At InnoSer, we take a collaborative approach to advancing your research, allowing you to be more involved than ever in your outsourced research.

### Flexibility

Our flexibility allows us to provide tailored and custom solutions with your needs as our top priority.

### Make a difference

Our studies are performed with the ultimate goal of providing faster access to the most efficient treatments to those who need it the most.

"Together, we are flexible and eager to make a difference."

## Well-characterized & Translationally Relevant Research Models

InnoSer study experts deliver you with the necessary expertise, experience, and tailor-made scientific advice spanning from immuno-oncology, neurological, cardio-metabolic, to rare genetic diseases.

### Model neurological conditions: Neurology

Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Duchenne Muscular Dystrophy
Neuropsychiatric disorders
Spasticity

### Meet the unmet medical need: Rare Genetic Diseases

Polycystic Kidney Disease
*STXBP1* Infantile Epileptic Encephalopathy
Fragile X Syndrome
Vanishing White Matter
Charcot Marie Tooth Disease Type 1A

### Develop silver bullets: Immuno-Oncology

CDX tumor models
PDX/O models
Syngeneic tumor models
Immunization
Inflammation models

### Target one of the most prevalent diseases: Cardiometabolic Diseases

Myocardial infarction
Heart failure
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Liver inflammation and fibrosis
NASH/NAFLD

# Evaluate Your Compound's Efficacy in Your Model of Choice




## Test putative Alzheimer's Disease therapeutics using in vivo models

In ARTE10 mice, methoxy-X04 positive amyloid plaque deposition is detected at 6M, which becomes more pronounced at 10M. This is associated with reactive astrocytes (GFAP) around the plaques.




## Model different progression stages of polycystic kidney disease

The age-dependent nature of cyst formation in our uniquely engineered *Pkd1* knockout model enables you to choose the most appropriate study design to answer your research question.




## Demonstrate efficacy profiles of novel therapies in immunocompetent mice

Access InnoSer's panel of validated syngeneic models suitable for immunotherapy evaluation.




## Target one of the most prevalent cardiometabolic disorders

NASH mice show liver steatosis, cognitive deficits and altered blood liver disease markers.

# Seamlessly Navigate the Drug Development Pipelines with InnoSer's Customized & Streamlined Research Options

Besides scientific expertise across various therapeutic fields, experts at InnoSer help you seamlessly move from one stage to another.

## Drug Discovery & Development Platform

**Small molecules**
**Biologics**
**Vaccines**
**ATMPs**
**Medical devices**




### Target relevance & druggability

- Primary samples
- Biomarkers
- Histopathology

### Early pharmacology, safety & efficacy leads

- Cellular models
- In vitro ADME(T)
- Pharmacometrics
- Biocompatibility

### Safety & efficacy to produce clinical candidate

- In vivo services
- Rodent disease models
- Dose-finding
- In vivo DMPK

### 

- Nonclinical safety
- Safety and toxicology
- Pharmacometrics
- Histopathology

# High Value Readouts Complementary to the Research Models

| | |
|---|---|
| **In vitro** | High content imaging<br>Live cell imaging |
| **In vivo** | Bioluminescence imaging<br>Ultrasound<br>Biomarker assays<br>Flow cytometry |
| **Behavioural phenotyping** | Cognitive tests<br>Automated tests (PhenoTyper ™)<br>Motor function<br>Anxiety/activity tests<br>Sensorimotor tests<br>Social behaviour |
| **Biotechnical capabilities** | Confocal microscopy<br>Compound administration, stereotactic surgery<br>Bioanalysis<br>Multiplex assays<br>EEG, EMG recording and data analysis<br>AHCODA™ data analysis |
| **Histopathology** | Routine but high-volume H&E<br>Single and multiplex IHC and IF<br>(Fluorescence) in situ hybridization<br>Digital histopathology solutions |




## Monitor the real-time regression of tumour growth following administration of your compound with bioluminescence imaging

Stable mouse and human tumour cell lines expressing luciferase serve to assess tumorigenicity in subcutaneous, intravenous and metastatic models.

## Measure the impact of your compound on discrimination learning with our proprietary and automated CognitionWall™

The CognitionWall™ contains three entrances; mice are rewarded with food pellet when they choose to pass through one of the entrances. The rate at which a mouse gains a preference for the rewarded entrance is used as a measure of discrimination learning.












## Assess in-depth neuronal activity changes using EEG recording

Wireless EEG implants in freely moving mice allow the detection of EEG abnormalities such as spike-wave discharges. Combined EMG and video footage allows accurate epileptic phenotype recording.